Posted by Michael Wonder on 05 May 2020
FDA approves new treatment for a type of heart failure
5 May 2020 - Today, the U.S. FDA approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalisation for heart failure.
With the approval, Farxiga is the first in this particular drug class, sodium-glucose co-transporter 2 (SGLT2) inhibitors, to be approved to treat adults with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.
Farxiga was shown in a clinical trial to improve survival and reduce the need for hospitalisation in adults with heart failure with reduced ejection fraction.
